title: Where VC Fears To Tread.
abstract: In recent years, venture capitalists have been less willing to place bets on pre-clinical technologies. Major drug manufacturers, flush with cash but increasingly bereft of blockbusters, are stepping into the breach. So are established biotech companies. Here's a look at how the changing sources and timing of investments are helping to shape biotech's future.
authors.affiliation: Senior contributing editor Patrick Mullen is a freelance writer in Cleveland Heights, Ohio.
authors.forename: Patrick
authors.initials: P
authors.lastname: Mullen